C21 Investments (OTC: CXXI) and Vext Science (OTC: VEXT) have demonstrated notable financial performance, particularly in cash flow and credit stability. This is significant given the challenges faced by many larger cannabis companies. Despite market caps of $29.98 million for Vext and $33.33 million for C21, they outperform larger peers like Tilray (NASDAQ: TLRY) with a market cap of $1.53 billion, Curaleaf (OTC: CURLF) with a market cap of $3.10 billion, and Trulieve (OTC: TCNNF) with a market cap of $1.69 billion. Comparative Analysis With Major Cannabis Stocks The leveraged free Cash Flow Margin (LFCFM) indicates how efficiently a company converts its revenue into cash after covering operating expenses, debt interests and capital expenditures. C21 Investments has an LFCFM of 12.3%, while Vext Science has an LFCFM of 4.1%. C21 Investments and Vext Science's performance metrics are compared with major cannabis stocks like Verano Holdings (OTC: VRNOF), Green Thumb (OTC: GTBIF), Trulieve, and Curaleaf Holdings. For comparison, Verano Holdings has an LFCFM of 9.3% with a ...